Empagliflozin + Placebo + Sitagliptin + Placebo

Phase 3Withdrawn
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Jan 1, 2015 โ†’ Feb 1, 2017

About Empagliflozin + Placebo + Sitagliptin + Placebo

Empagliflozin + Placebo + Sitagliptin + Placebo is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01984606. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01984606Phase 3Withdrawn